Capricor Therapeutics, Inc. (CAPR) — Stock Score Summary

Capricor Therapeutics, Inc. (CAPR) has a MoatMap StockRank of 39/100 based on Quality (34/100), Value (36/100), and Momentum (56/100) factor scores. The current signal is HOLD. Capricor Therapeutics is a clinical-stage biotech company. It is highly speculative, unprofitable, and lacks the established commercial moat and high ROIC required for our concentrated portfolio.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative biological therapeutics for serious diseases, primarily Duchenne muscular dystrophy. Its competitive edge comes from a proprietary cell therapy platform and focus on unmet medical needs in rare diseases, potentially securing significant market share. Capricor is a niche biopharmaceutical company leveraging regenerative medicine approaches, advancing late-stage clinical trials for rare genetic disorders.

Key Financial Metrics

Price$26.01
Market Cap$1.7B
P/E (Forward)-36.60
Price/Book5.78
Return on Equity-56.4%
Return on Invested Capital-31.9%
Debt/Equity5.30
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-70M

Capricor Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Capricor Therapeutics, Inc.’s (CAPR) StockRank?
MoatMap’s StockRank for Capricor Therapeutics, Inc. (CAPR) is 39/100, with a Hold signal. It is a composite of Quality (34), Value (36), and Momentum (56) factor ranks across MoatMap’s 19,000+ stock universe.
Does Capricor Therapeutics, Inc. have an economic moat?
Capricor Therapeutics, Inc. (CAPR) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Capricor Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Capricor Therapeutics, Inc. (CAPR) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Capricor Therapeutics, Inc. in?
Capricor Therapeutics, Inc. (CAPR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCAPR deep dive reportAI ChampionsHow we score stocksSense-check another stock